Beyond antifungals: vaginal ceramides as a barrier-restorative strategy for recurrent vulvovaginal candidiasis in Ehlers-Danlos syndrome
Year: 2026
Type: article
Abstract: To the Editor, Recurrent vulvovaginal candidiasis (RVVC) is a chronic and irritating disease characterized by three or more symptomatic occurrences of vulvovaginal candidiasis in a year. It is a condition that severely undermines women’s physical, sexual, and psychological health. The majority of infected women fall into the reproductive age group, with a median of 29 years, and the main causative agent is Candida albicans, which accounts for 92.5% of isolates, followed by Candida lusitaniae at 7.5%. The difficulty in managing the infection is compounded by the emergence of azole-resistant strains, which leads to recurring and sometimes permanent infections. Immunology-based studies demonstrate that women suffering from RVVC exhibit less neutrophil activity and have C. albicans immune responses that differ from the normal ones, thus making it clear that the infection has a multifactorial nature and is a large health problem worldwide[1]. RVVC is further complicated in patients with Ehler-Danlos syndrome (EDS), a heterogeneous group of connective tissue disorders, where varying degrees of tissue fragility and impaired barrier function may lead to recurrent infections[2], underscoring the therapeutic potential of vaginal ceramides to improve vaginal defense and the integrity of the vulvovaginal epithelial barrier. Candida adherence and colonization in the vagina are normally balanced by host immunity and microbiota; however, factors like impaired innate immune responses disrupt this homeostasis, leading to recurrent infections[3]. Recent clinical studies indicate that EDS is associated with serious urogenital complications, including vaginal dryness, genital fissures, and recurrent vaginal infections, which are largely due to underlying collagen defects[2]. Such a connective tissue integrity defect may lead to a fragile vulvovaginal epithelium, facilitating Candida adherence and immune dysregulation, and predisposing to recurrence of vulvovaginal candidiasis. Emerging clinical findings show that ceramides are an essential component of the lipid barrier of both skin and mucosa, playing a key role in maintaining barrier integrity and defending against pathogens, suggesting a novel approach for preventing RVVC in EDS[4]. Current RVVC management depends on antifungal azoles like fluconazole. However, increasing resistance and limited long-term efficacy remain major challenges in continued treatment. One of the key contributors to this antifungal resistance is biofilm formation by Candida, which promotes recurrence and increases drug tolerance[5]. Newer agents such as oteseconazole and ibrexafungerp show promising results in light of these challenges; their use is limited by safety and availability issues, while vaccines like NDV-3A are still under study. Notably, existing strategies widely neglect mucosal barrier integrity, critical in EDS, which highlights the need to switch from antimicrobial therapy alone toward barrier restoration interventions, such as ceramides[6]. Despite the theoretical promise of vaginal ceramides, several important clinical limitations need to be addressed. First, no direct clinical evidence for vaginal ceramide therapy in women with EDS was found, with subtype-related mucosal heterogeneity potentially impacting treatment outcomes, safety, and generalizability[2]. Moreover, most ceramide research has concentrated on skin, which has left the vulvovaginal mucosal barrier largely uncharacterized; due to this, its tolerability in non-cutaneous environments and long-term efficacy remain unclear[3]. Finally, the combined effect of specific ceramide formulations with existing antifungals and their long-term influence on recurrence and vaginal mucosal health requires thorough investigation. The case of RVVC in EDS highlights a major drawback of nowadays azole-centric approaches, since the combination of collagen-induced weakness in the epithelium with Candida biofilm and immune dysregulation already requires not just the microbial suppression but also some other methods of intervention[1,2,5]. Vaginal ceramides, by restoring the mucosal lipid barriers, can directly prevent the pathogens from adhering to the cells, and at the same time, the tissue integrity gets damaged in this segment of the population, thus replacing a mechanistic gap that has not been covered by the new agents oteseconazole or ibrexafungerp[4,6]. There is an urgent need for clinicians to initiate subtype-stratified trials that combine ceramides with antifungals to determine tolerability and recurrence endpoints in EDS[2]; investigators must explore ceramide distribution and longevity in vulvovaginal mucosa compared to cutaneous models[3,4]; and stakeholders should financially support prospective cohorts that assess barrier function, biofilm burden, and patient-reported outcomes to validate this adjunctive, barrier-restorative strategy[5,6]. In summary, the novel use of vaginal ceramides for managing RVVC represents a physiologically sound, patient-centric, and mechanism-based adjunct to current therapies aiming to restore barrier integrity and decrease susceptibility to infection. This barrier repair approach revolutionizes RVVC treatment in EDS patients, where barrier dysfunction and immune modulation may potentiate recurrence, which cannot be managed by conventional antifungal therapy alone. Through further research, optimizing formulations, and safe dosing regimens, a multifaceted approach has the potential to fill a significant gap in current management with the ultimate goal of improving quality of life. This letter to the editor adheres to the Transparency in the Reporting of Artificial Intelligence in Research (TITAN) guideline[7]. During the preparation of this manuscript, generative AI tools (DeepSeek, DeepSeek Inc., June 2025 version; temperature parameter = 0.7) were used only as auxiliary aids to assist in formatting standardization, organization of background information, and language consistency checks. All AI-assisted text was thoroughly reviewed, edited, and refined by the authors. The conceptualization, literature interpretation, synthesis of ideas, and manuscript writing were performed entirely by the authors, ensuring the academic rigor, accuracy, and originality of the review.
Source: Annals of Medicine and Surgery
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,850
OpenAlex ID: W7123598433